S&P 500   3,338.34 (-0.32%)
DOW   27,320.86 (-0.24%)
QQQ   270.38 (-1.55%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
S&P 500   3,338.34 (-0.32%)
DOW   27,320.86 (-0.24%)
QQQ   270.38 (-1.55%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
S&P 500   3,338.34 (-0.32%)
DOW   27,320.86 (-0.24%)
QQQ   270.38 (-1.55%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
S&P 500   3,338.34 (-0.32%)
DOW   27,320.86 (-0.24%)
QQQ   270.38 (-1.55%)
AAPL   444.31 (-2.48%)
MSFT   211.70 (-2.15%)
FB   270.05 (+1.80%)
GOOGL   1,496.75 (-0.54%)
AMZN   3,162.76 (-1.93%)
NVDA   445.46 (-1.76%)
CGC   16.83 (-3.94%)
BABA   248.55 (-6.45%)
TSLA   1,436.04 (-3.59%)
MU   48.26 (-0.90%)
GE   6.39 (+0.95%)
AMD   83.36 (-3.86%)
T   29.95 (+0.37%)
F   6.85 (-1.15%)
ACB   10.12 (-1.84%)
GILD   69.02 (+0.31%)
NFLX   490.47 (-3.66%)
DIS   130.62 (-0.15%)
BAC   26.18 (+2.79%)
BA   170.11 (-1.21%)
Log in

NASDAQ:CVETCovetrus Stock Price, Forecast & News

$22.84
-0.37 (-1.59 %)
(As of 08/7/2020 02:13 PM ET)
Add
Compare
Today's Range
$22.76
Now: $22.85
$23.77
50-Day Range
$17.34
MA: $19.62
$23.04
52-Week Range
$4.05
Now: $22.85
$24.38
Volume294,117 shs
Average Volume858,865 shs
Market Capitalization$2.56 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.85
Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.05 out of 5 stars


Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
Current SymbolNASDAQ:CVET
CUSIPN/A
CIKN/A
Phone888-280-2221

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.98 billion
Cash Flow$10.63 per share
Book Value$11.20 per share

Profitability

Net Income$-1,019,000,000.00

Miscellaneous

Employees5,500
Market Cap$2.56 billion
Next Earnings Date8/11/2020 (Confirmed)
OptionableNot Optionable
$22.84
-0.37 (-1.59 %)
(As of 08/7/2020 02:13 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for CVET and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Covetrus (NASDAQ:CVET) Frequently Asked Questions

How has Covetrus' stock been impacted by COVID-19 (Coronavirus)?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CVET shares have increased by 152.7% and is now trading at $22.8450.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Covetrus?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Covetrus
.

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Covetrus
.

How can I listen to Covetrus' earnings call?

Covetrus will be holding an earnings conference call on Tuesday, August 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Covetrus' earnings last quarter?

Covetrus Inc (NASDAQ:CVET) issued its quarterly earnings data on Thursday, May, 14th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.12 by $0.06. The business earned $1.07 billion during the quarter, compared to analysts' expectations of $1.07 billion. Covetrus had a negative net margin of 24.05% and a positive return on equity of 4.84%.
View Covetrus' earnings history
.

What price target have analysts set for CVET?

4 brokers have issued 1 year price objectives for Covetrus' stock. Their forecasts range from $11.00 to $21.00. On average, they expect Covetrus' stock price to reach $16.00 in the next twelve months. This suggests that the stock has a possible downside of 30.0%.
View analysts' price targets for Covetrus
.

Has Covetrus been receiving favorable news coverage?

Media coverage about CVET stock has trended positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Covetrus earned a news impact score of 2.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Covetrus
.

Are investors shorting Covetrus?

Covetrus saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 11,040,000 shares, a decline of 6.5% from the July 15th total of 11,810,000 shares. Based on an average daily volume of 1,530,000 shares, the short-interest ratio is currently 7.2 days. Approximately 11.3% of the company's shares are sold short.
View Covetrus' Current Options Chain
.

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include NVIDIA (NVDA), Enterprise Products Partners (EPD), AT&T (T), Verizon Communications (VZ), Evolent Health (EVH), Alphabet (GOOG), IDEXX Laboratories (IDXX), Las Vegas Sands (LVS), Nokia Oyj (NOK) and Pfizer (PFE).

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Benjamin J. Shaw, President, Chief Executive Officer & Director
  • Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
  • Matthew Leonard, Executive VP & President-North America
  • Jim Young, Chief Human Resources Officer & Senior VP
  • Erin Powers Brennan, Secretary, Senior Vice President & General Counsel

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by a variety of institutional and retail investors. Top institutional investors include BNP PARIBAS ASSET MANAGEMENT Holding S.A. (1.30%), Palisade Capital Management LLC NJ (0.82%), Principal Financial Group Inc. (0.66%), New York State Common Retirement Fund (0.21%), Swiss National Bank (0.20%) and WINTON GROUP Ltd (0.15%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Edward Mcnamara, Erin Powers Brennan and Timothy Ludlow.
View institutional ownership trends for Covetrus
.

Which major investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including BNP PARIBAS ASSET MANAGEMENT Holding S.A., Russell Investments Group Ltd., UBS Group AG, Principal Financial Group Inc., New York State Common Retirement Fund, Westside Investment Management Inc., M&T Bank Corp, and Country Club Trust Company n.a.. Company insiders that have sold Covetrus company stock in the last year include Edward Mcnamara, and Timothy Ludlow.
View insider buying and selling activity for Covetrus
.

Which major investors are buying Covetrus stock?

CVET stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, WINTON GROUP Ltd, Swiss National Bank, Centric Wealth Management, New York State Teachers Retirement System, ProShare Advisors LLC, Ameritas Investment Partners Inc., and Comerica Bank. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw, and Erin Powers Brennan.
View insider buying and selling activity for Covetrus
.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $22.85.

How big of a company is Covetrus?

Covetrus has a market capitalization of $2.56 billion and generates $3.98 billion in revenue each year. The company earns $-1,019,000,000.00 in net income (profit) each year or $0.79 on an earnings per share basis. Covetrus employs 5,500 workers across the globe.

What is Covetrus' official website?

The official website for Covetrus is www.henryscheinvet.com.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.